Metformin Downregulates the Insulin/IGF-I Signaling Pathway and Inhibits Different Uterine Serous Carcinoma (USC) Cells Proliferation and Migration in p53-Dependent or -Independent Manners
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Accumulating epidemiological evidence shows that obesity is associated with an increased risk of several types of adult cancers, including endometrial cancer. Chronic hyperinsulinemia, a typical hallmark of diabetes, is one of the leading factors responsible for the obesity-cancer connection. Numerous cellular and circulating factors are involved in the biochemical chain of events leading from hyperinsulinemia and insulin resistance to increased cancer risk and, eventually, tumor development. Metformin is an oral anti-diabetic drug of the biguanide family used for treatment of type 2 diabetes. Recently, metformin was shown to exhibit anti-proliferative effects in ovarian and Type I endometrial cancer, although the mechanisms responsible for this non-classical metformin action remain unclear. The insulin-like growth factors (IGFs) play a prominent role in cancer biology and their mechanisms of action are tightly interconnected with the insulin signaling pathways. Given the cross-talk between the insulin and IGF signaling pathways, the aim of this study was to examine the hypothesis that the anti-proliferative actions of metformin in uterine serous carcinoma (USC) are potentially mediated via suppression of the IGF-I receptor (IGF-IR) pathway. Our results show that metformin interacts with the IGF pathway, and induces apoptosis and inhibition of proliferation and migration of USC cell lines with both wild type and mutant p53. Taken together, our results suggest that metformin therapy could be a novel and attractive therapeutic approach for human USC, a highly aggressive variant of endometrial cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Metformin is shown to decrease insulin and IGF-1 levels and downregulate IIS in cancer cells”
From Benefits of Metformin in Attenuating the Hallmarks of Aging (2020) · cites this paper as Sarfstein et al. 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Sarfstein, R., Belfiore, A., & Werner, H. (2010) · Cancers · doi:10.3390/cancers2020233 · Cited by 31 · cited 2×
“USPC-1 and USPC-2 cells were transfected as previously described [28,29].”
BackgroundMethodSelf-citationRetractedp53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · cited 1×
“Part of these, seemingly, paradoxical results can be explained by the fact that Ishikawa cells are known to have mutations in the ras protooncogene, p53 [45] and pTen tumor suppressor gene, leading to constitutive phosphorylation of AKT [46].”
ResultThe phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056 · cited 2×
“Deregulation of this fine balance might lead to metabolic growth related diseases, resistance to apoptosis, and increased proliferation [55,56].”
BackgroundRole of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 1×
“In vitro and in vivo studies showed increased peripheral insulin sensitivity and cancer growth inhibition by Ampk activation [27].”
BackgroundDefining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833 · cited 1×
“This was associated with decreased AKT activation [33], which led to reduced mTOR activation [23,34].”
BackgroundInsulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059 · cited 2×
“This was associated with decreased AKT activation [33], which led to reduced mTOR activation [23,34].”
BackgroundGuba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., et al. (2002) · Nature Medicine · doi:10.1038/nm0202-128 · Cited by 1,739 · cited 1×
“cell proliferation in a number of experimental systems [12–15].”
BackgroundA Detergent‐trypsin method for the preparation of nuclei for flow cytometric DNA analysis
Vindeløv, L. L., Christensen, I. J., & Nissen, N. I. (1983) · Cytometry · doi:10.1002/cyto.990030503 · Cited by 1,639
The tor pathway: a target for cancer therapy
Bjornsti, M.-A., & Houghton, P. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1362 · Cited by 1,314 · cited 1×
“Deregulation of this fine balance might lead to metabolic growth related diseases, resistance to apoptosis, and increased proliferation [55,56].”
BackgroundObesity, endogenous hormones, and endometrial cancer risk: a synthetic review.
Kaaks, R., Lukanova, A., & Kurzer, M. S. (2002) · PubMed · Cited by 1,199
Research works printed but not linked: 1
- Bruchim I, Attias Z, Werner H (2009) Targeting the IGF1 axis in cancer proliferation. Expert Opin Ther Targets 13: 1179– 1192. 19663648 · DOI
Cited by
Items 101–151 of 151
Hamilton, N. M., Márquez‐Garbán, D. C., Mah, V. H., Elshimali, Y., Elashoff, D. A., Garon, E. B., Vadgama, J. V., & Pietras, R. J. (2015) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v20.i5-6.100 · Cited by 8
Teng, M., Li, Z., Gu, Y., Fan, Y., Wang, D., Liu, M., Li, Y., Wei, G., & Huang, Y. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.149383 · Cited by 7
Metformin Associates With Aggressive Features of Endometrial Cancer in Women With Type 2 Diabetes
Urpilainen, E., Arima, R., Karihtala, P., Puistola, U., & Ahtikoski, A. M. (2021) · Anticancer Research · doi:10.21873/anticanres.14834 · Cited by 7
Extension of Life Span in Laboratory Mice
Unnikrishnan, A., Deepa, S. S., Herd, H. R., & Richardson, A. G. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811353-0.00019-1 · Cited by 8
Bruchim, I., Sarfstein, R., Reiss, A., Flescher, E., & Werner, H. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.06.013 · Cited by 6
“165 [10].”
Self-citationSuh, D. H., Lee, S., Park, H.-S., & Park, N. H. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113585 · Cited by 5
“Other studies confirmed that there was no significant increase in p-AMPKα expression at low doses of metformin, ≤1000 μM, in Ishikawa, KLE, and USPC cells [23,26,27].”
BackgroundBakhashab, S., O’Neill, J., Barber, R., Arden, C., & Weaver, J. U. (2024) · Biomedicines · doi:10.3390/biomedicines12010171 · Cited by 6
“It has pleiotropic effects, many of which are implicated in maintaining cardiovascular health [25,26].”
BackgroundMapping the current research landscape of metformin in cancer based on bibliometric analysis
Wang, Y., He, S., Li, Z., Jiang, N., & Sun, G. (2025) · Discover Oncology · doi:10.1007/s12672-025-03327-z · Cited by 5
“As an insulin sensitizer, metformin decreases plasma insulin and insulin-binding proteins, thereby lowering insulin-like growth factor-1 (IGF-1) levels and attenuating IGF-1-mediated cell proliferation signals, which contributes to tumor growth inhibition [32, 54].”
Metformin Impairs Linsitinib Anti-Tumor Effect on Ovarian Cancer Cell Lines
Almeida-Nunes, D. L., Silva, J. P. N., Nunes, M., Silva, P. M. A., Silvestre, R., Dinis‐Oliveira, R. J., Bousbaa, H., & Ricardo, S. A. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252211935 · Cited by 4
Salah, H., Rabea, H., Sheemy, M. S., Rabie, A. S. I., Moustafa, H. A. M., Elberry, A. A., & Hassan, A. (2025) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-025-04791-8 · Cited by 5
“IGF-1 has oncogenic and mitogenic properties and although its concentrations differ due to many factors, such as age and obesity, overexpression of the IGF-1 receptor has been reported in many cancers [14, 39].”
Singh, S. S. B., Eligar, S. M., & Patil, K. N. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c07776 · Cited by 4
Clinical prospects of IGF-signaling system components study in ovarian cancer patients
Герштейн, Е. С., & Кушлинский, Н. Е. (2015) · Drug Metabolism and Personalized Therapy · doi:10.1515/dmdi-2014-0037 · Cited by 4
Antitumoral Effects of Metformin in Ovarian Cancer
Garrido, M. P., Vega, M., & Romero, C. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.88911 · Cited by 5
“Some studies have shown that metformin treatment decreases IGF-1 and insulin levels, in a mice model with ovarian cancer [51], and also metformin treatment blocks the pro-tumoral effects of the nerve growth factor (NGF) in epithelial ovarian cancer cells [35] or the insulin/IGF-I signaling in uterine serous carcinoma…”
BackgroundInsulin and Insulin-Like Growth Factor-1 Associated Cancers
Dey, S. K., & Senapati, S. (2021) · Springer eBooks · doi:10.1007/978-981-16-1846-8_3 · Cited by 7
Campbell, J. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.62141-4 · Cited by 4
Yeom, S., Lee, D. H., & Song, J. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70446 · Cited by 5
“This dual suppression of IGF-1 and insulin signaling is a key mechanism by which metformin exerts its anti-tumorigenic effects across various cancers [138–141].”
Juárez-Vázquez, C. I., Gurrola‐Díaz, C. M., Vargas‐Guerrero, B., Domínguez-Rosales, J. A., Rodríguez-Ortiz, J. F., Barros‐Núñez, P., Flores-Martínez, S. E., Sánchez‐Corona, J., & Reynoso, M. A. R. (2018) · PubMed Central · doi:10.22038/ijbms.2018.24867.6185 · Cited by 6
“Although it has been reported that metformin inhibits cell proliferation by activating AMPK, which counteracts the PI3K/AKT and MAPK pathways downstream of the insulin-IGF1 receptors (58), and moreover, that metformin downregulates the insulin/IGF-I signaling pathway (59-61), researchers (62) observed overexpression o…”
BackgroundNozhat, Z., Zarkesh, M., Baldini, E., Mohammadi‐Yeganeh, S., Azizi, F., & Hedayati, M. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210118093532 · Cited by 3
Molecular Pathogenesis of Uterine Serous Carcinoma
Nagase, S., Suzuki, F., Tokunaga, H., Toyoshima, M., Utsunomiya, H., Niikura, H., & Yaegashi, N. (2013) · Current Obstetrics and Gynecology Reports · doi:10.1007/s13669-013-0069-0 · Cited by 2
Wei, R., Yu, F., Yang, J. M., Gao, H., Wang, H., & Hong, T. (2018) · Cell Biology International · doi:10.1002/cbin.10925 · Cited by 2
“It has been shown that metformin inhibits tumor cell proliferation via downregulating the insulin/IGF-1 signalling (Karnevi et al., 2013; Sarfstein et al., 2013; Kato et al., 2015).”
BackgroundMunday, J. S., Odom, T., Dittmer, K. E., Wetzel, S., Hillmer, K., & Tan, S. T. (2022) · Veterinary Sciences · doi:10.3390/vetsci9080411 · Cited by 2
“Conversion of prorenin to renin is also inhibited by curcumin, which inhibits the cathepsins, and by metformin, which reduces renin production by inhibiting insulin-like growth factor 1 [14,15].”
BackgroundCampbell, J. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823679-6.00013-8 · Cited by 2
EVOLUTION OF METFORMIN IN BREAST CANCER THERAPY IN LAST TWO DECADES: A REVIEW
Sarathi, R., Sarumathy, S., & Mavalavan, V. M. D. (2024) · Experimental Oncology · doi:10.15407/exp-oncology.2024.03.185 · Cited by 2
“In vitro studies have shown that metformin suppresses the development of several human cancer cell lines by regulating glucose metabolism and the PI3KAKT mTOR signaling pathway [11, 12].”
RNA and protein degradation in the aging process
Lin, J., Qiu, Y., Ye, C., Zhang, Y., Zeng, Z., Yao, B., Hu, Y., & Zhao, L. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.112166 · Cited by 1
Oriaifo, S. E. (2015) · International Research Journal of Medicine and Medical Sciences · doi:10.14303/jmms.2015.116 · Cited by 1
“Inhibition of the mammalian target of rapamycin (mTOR) signalling and its downstream target, S6KI coupled with suppression of the IGF – IR signalling (Sarfstein et al., 2013), by metformin increases insulin sensitivity, induces autophagy (Perez-Revuelta et al., 2014; Renna et al., 2010) and may be…”
BackgroundMetformin in ovarian cancer therapy: A discussion
Guo, J., Ouyang, Y., Chen, X., Zhang, C., & Bunyamanop, V. (2016) · Cancer translational medicine · doi:10.4103/2395-3977.189306 · Cited by 1
Targeted Therapy in Management of Endometrial Cancer
Lee, Y. C., Lheureux, S., Mirza, M. R., & Oza, A. M. (2019) · Springer eBooks · doi:10.1007/978-3-319-64513-1_18 · Cited by 1
Pharmacological interventions part IV: Metabolic modifiers
Koltai, T., Reshkin, S. J., & Harguindey, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819059-3.00016-2 · Cited by 2
Amălinei, C., Balan, R. A., & Lozneanu, L. (2022) · Handbook of Oxidative Stress in Cancer: Therapeutic Aspects · doi:10.1007/978-981-16-5422-0_233 · Cited by 1
Xie, Y., Liang, Y., Ping, P., Li, Y., Zhang, Q., & Lin, Z. (2023) · Journal of Radiation Research and Applied Sciences · doi:10.1016/j.jrras.2023.100580 · Cited by 1
Dittmer, K. E., Wetzel, S., Odom, T., Munday, J. S., Flatt, E. A., Wilson, I. J., Hughes, C., & Tan, S. T. (2024) · Veterinary Sciences · doi:10.3390/vetsci11060275 · Cited by 1
“The conversion of prorenin to renin is blocked using atenolol (a β -blocker that decreases renin production [12,13]), meloxicam (a COX2 inhibitor [14]), curcumin (a cathepsin B inhibitor [15]), and metformin (an inhibitor of the IGF-1 signaling pathway [16,17]).”
BackgroundSpontankonzeption vor geplanter Assistierter Reproduktionstechnik (ART): Inzidenz und Outcome
Class, H. (2017) · University of Regensburg Publication Server (University of Regensburg) · doi:10.5283/epub.35554 · Cited by 1
THE METABOLOMIC EFFECTS OF METFORMIN ON COLON CANCER
Harris, J. W. (2015) · UKnowledge (University of Kentucky)
Metformin Induces Ultrastructural Alterations in Hepatocytes of Spontaneously Hypertensive Rats
Gharbaran, R. (2014) · International Journal of Morphology · doi:10.4067/s0717-95022014000300016
Ajonijebu, D. C. (2013) · Journal of Carcinogenesis & Mutagenesis · doi:10.4172/2157-2518.s6-007
“Although the cell is equipped with the metabolic machinery to stitch the broken genetic fragments during replication, it is however not endowed with tools to recognize the actual sites [15-20].”
BackgroundPines, A. (2014) · Climacteric · doi:10.3109/13697137.2014.884273
Metformin as Adjuvant Therapy in Ovarian and Endometrial Cancers
Clark, L. H., & Bae-Jump, V. L. (2017) · Energy balance and cancer · doi:10.1007/978-3-319-63483-8_16
Metformin as a potential therapy for malignant astrocytoma
Eagles, L. (2018) · Wolverhampton Intellectual Repository and E-Theses (University of Wolverhampton)
Balarezo, L. F. G. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2019.tde-23102019-170254
Diabetes mellitus indicate poor prognosis in uterine serous cancer patientsPreprint
Liu, Y., Li, J., Cheng, Z., Xu, G., Peng, Y., & Huaiwu, L. (2021) · Research Square · doi:10.21203/rs.3.rs-261282/v1
The conductors of the metabolic orchestra
Koltai, T., Reshkin, S. J., Baltazar, F., & Fliegel, L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90528-2.00006-0
Metformin and endometrial cancer risk: A Meta-analysisPreprint
Xie, W., & Wen, D. (2019) · doi:10.21203/rs.2.19317/v1
Amălinei, C., Balan, R. A., & Lozneanu, L. (2022) · Handbook of Oxidative Stress in Cancer: Therapeutic Aspects · doi:10.1007/978-981-16-1247-3_233-1
Wen, Q., Zhao, Z., Wen, J., Zhou, J., Wu, J., Lei, S., & Miao, Y. (2019) · European Journal of Obstetrics & Gynecology and Reproductive Biology X · doi:10.1016/j.eurox.2019.100010
Association of the FTO gene with obesity and cancer in dogs
BEDİK, D., Kırmızıoğlu, G., & Akış, I. (2023) · Journal of Istanbul Veterinary Sciences · doi:10.30704/http-www-jivs-net.1349652
Old Drugs: Confronting Recent Advancements and Challenges
(2025) · Frontiers research topics · doi:10.3389/978-2-8325-6198-0
Zhang, Y., Liu, X., Lian, H., Chai, Y., Zhou, Y., Kan, D., Ren, J., Han, C., & Yang, J. (2025) · Aging Cell · doi:10.1111/acel.70113 · Cited by 1
Antitumor Effects of Metformin in Squamous Cell Carcinoma under Leptin Treatment Conditions
Yeom, S., Jo, D., Choi, S. Y., Ahn, S. Y., Lee, D. H., & Song, J. (2025) · Preventive Nutrition and Food Science · doi:10.3746/pnf.2025.30.4.312
“Metformin also reduces insulin like growth factor 1 and insulin signaling, which suppresses the activation of the PI3K/AKT/mTOR and RAS/MAPK/ERK pathways that promote cell proliferation and survival (Sarfstein et al., 2013; Xie et al., 2014; Kato et al., 2015).”
Efeito da metformina sobre a via de sinalização do IGF-1R no câncer de endométrio
dos Reis, V. M. S. F. (2023) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 2
Benjamin, M., Sharawat, S. K., & Chopra, A. (2026) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-026-00869-y
Metadata
- Authors
- Sarfstein, R., Friedman, Y., Attias-Geva, Z., Fishman, A., Bruchim, I., & Werner, H.
- Affiliations
- Tel Aviv University (IL)
- Meir Medical Center (IL)
- Corresponding author
- Werner, Haim
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-04-19
- Volume
- 8
- Issue
- 4
- Pages
- e61537
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3631250
- OpenAlex
- W2009665800
- Cited by
- 150
- References
- 58
- Citations by year
- 2026: 1 · 2025: 11 · 2024: 6 · 2023: 6 · 2022: 11 · 2021: 14 · 2020: 14 · 2019: 14 · 2018: 11 · 2017: 10 · 2016: 16 · 2015: 11 · 2014: 22 · 2013: 3
- FWCI
- 7.77
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- metformin, uterine serous carcinoma, IGF-1 receptor, p53, apoptosis, cell proliferation, cell migration, endometrial cancer, hyperinsulinemia, biguanides
- MeSH terms
- Forkhead Box Protein O1, Glycogen Synthase Kinase 3 beta, Adenylate Kinase, Cell Cycle, Cell Movement, Cell Survival, Female, Humans, Insulin, Insulin-Like Growth Factor I, Metformin, Phosphorylation, Promoter Regions, Genetic, Receptor, Insulin, Uterine Neoplasms, Signal Transduction, Down-Regulation, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Endometrial Neoplasms, Apoptosis, Receptor, IGF Type 1, Cystadenocarcinoma, Serous, Glycogen Synthase Kinase 3, Cell Line, Tumor, Cell Proliferation, Forkhead Transcription Factors, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.